Bottom line
Is CANC a good fund? The bottom line
CANC is an actively managed large blend ETF from Innovator.
Annual fees run 0.75% — about $75 a year on every $10,000 invested, cheaper than 55% of large blend funds we track.
It returned +42.8% over one year (as of Dec 31, 2025, per its prospectus).
With $176 million in net assets and 57 holdings, its largest position is Revolution Medicines Inc (7.7%) and the top 10 make up 42.9% of the portfolio.
Updated Nov 19, 2026
What CANC invests in
Tema Oncology ETF (the Fund) seeks to provide long-term growth.
Under normal circumstances, the Fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The Tema ETF LLC (the Adviser), the Funds investment adviser, will use internal research and analysis based on company disclosure (such as 10-K filings, company presentations, capital markets day presentations) and other publicly available sources (e.g., sell-side research, biotechnology industry publications etc.) to make this assessment. Example companies include large pharmaceutical firms, diagnostic focused businesses with products used to diagnose cancer (such as liquid biopsies or cancer genomic screening), medical device companies focused on cancer treatment, and healthcare service providers with a specific strategic focus on…
From the fund's prospectus (filed Jun 29, 2026).
CANC performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| CANC | +42.8% | — | — |
| Large Blend median | +13.8% | +9.7% | +10.9% |
Source: Fund prospectus, as of Dec 31, 2025
What CANC costs
On a $10,000 investment, CANC's 0.75% expense ratio costs about $75 a year. The prospectus estimates $1,168 in total costs over 10 years (assuming 5% annual returns). The median large blend fund charges 0.83%.
CANC top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Revolution Medicines Inc RVMD | 7.73% |
| 2 | Eli Lilly & Co LLY | 4.82% |
| 3 | Roche Holding AG RHHBY | 4.21% |
| 4 | Cogent Biosciences Inc COGT | 4.10% |
| 5 | Novartis AG NOVN | 4.03% |
| 6 | Immunome Inc IMNM | 3.91% |
| 7 | Celcuity Inc CELC | 3.58% |
| 8 | Merck & Co Inc MRK | 3.57% |
| 9 | AstraZeneca PLC AZN | 3.54% |
| 10 | Nuvalent Inc NUVL | 3.37% |
Source: SEC Form N-PORT, period ended May 31, 2026
The top 10 make up 42.9% of the fund. See all top 25 holdings and asset mix →